Nanoparticles for the Regulation of Intestinal Inflammation: Opportunities and Challenges

References

• Ng SC , ShiHY , HamidiNet al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet390(10114), 2769–2778 (2017).
   PubMed Web of Science ®Google Scholar
• Kaplan GG , NgSC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology152(2), 313.e2–321.e2 (2017).
   Web of Science ®Google Scholar
• Khor B , GardetA , XavierRJ. Genetics and pathogenesis of inflammatory bowel disease. Nature474(7351), 307–317 (2011).
   PubMed Web of Science ®Google Scholar
• Ghosh S , MitchellR. Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey. J. Crohns Colitis1(1), 10–20 (2007).
   PubMed Web of Science ®Google Scholar
• Irvine EJ . Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm. Bowel Dis.14(4), 554–565 (2008).
   PubMed Web of Science ®Google Scholar
• Xavier RJ , PodolskyDK. Unravelling the pathogenesis of inflammatory bowel disease. Nature448, 427 (2007).
   PubMed Web of Science ®Google Scholar
• Taylor KM , IrvingPM. Optimization of conventional therapy in patients with IBD. Nat. Rev. Gastroenterol. Hepatol.8(11), 646–656 (2011).
   PubMed Web of Science ®Google Scholar
• Buchman AL . Side effects of corticosteroid therapy. J. Clin. Gastroenterol.33(4), 289–294 (2001).
   PubMed Web of Science ®Google Scholar
• Berends SE , StrikAS , LöwenbergM , D’HaensGR , MathôtRAA. Clinical pharmacokinetic and pharmacodynamic considerations in the treatment of ulcerative colitis. Clin. Pharmacokinet.58(1), 15–37 (2019).
   PubMed Web of Science ®Google Scholar
• Cunliffe RN , ScottBB. Monitoring for drug side-effects in inflammatory bowel disease. Aliment. Pharmacol. Ther.16(4), 647–662 (2002).
   PubMed Web of Science ®Google Scholar
• Aberra FN , LichtensteinGR. Review article: monitoring of immunomodulators in inflammatory bowel disease. Aliment. Pharmacol. Ther.21(4), 307–319 (2005).
   PubMed Web of Science ®Google Scholar
• Lautenschläger C , SchmidtC , FischerD , StallmachA. Drug delivery strategies in the therapy of inflammatory bowel disease. Adv. Drug Deliv. Rev.71(0), 58–76 (2014).
   PubMedGoogle Scholar
• Lamprecht A , SchaferU , LehrC-M. Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm. Res.18(6), 788–793 (2001).
   PubMed Web of Science ®Google Scholar
• Lamprecht A . Selective nanoparticle adhesion can enhance colitis therapy. Nat. Rev. Gastroenterol. Hepatol.7, 311 (2010).
   PubMed Web of Science ®Google Scholar
• Collnot EM , AliH , LehrCM. Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. J. Control. Rel.161(2), 235–246 (2012).
   PubMed Web of Science ®Google Scholar
• Xiao B , LarouiH , ViennoisEet al. Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. Gastroenterology146(5), 1289.e19–1300.e19 (2014).
   Web of Science ®Google Scholar
• Ali H , WeigmannB , NeurathMF , CollnotEM , WindbergsM , LehrC-M. Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases. J. Control. Rel.183, 167–177 (2014).
   PubMed Web of Science ®Google Scholar
• Wilson DS , DalmassoG , WangL , SitaramanSV , MerlinD , MurthyN. Orally delivered thioketal nanoparticles loaded with TNF-α–siRNA target inflammation and inhibit gene expression in the intestines. Nat. Mater.9, 923 (2010).
   PubMed Web of Science ®Google Scholar
• Nunes R , SarmentoB , ReisS , FonteP. Oral nanotechnological approaches for colon-specific drug delivery. In: Nanoparticles in the Life Sciences and Biomedicine. NevesAR, ReisS ( Eds). Panstanford Publishing, Oxon, UK, 133–158 (2018).
   Google Scholar
• Bansil R , TurnerBS. The biology of mucus: composition, synthesis and organization. Adv. Drug Deliv. Rev.124, 3–15 (2018).
   PubMed Web of Science ®Google Scholar
• Pullan RD , ThomasGA , RhodesMet al. Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. Gut35(3), 353–359 (1994).
   PubMed Web of Science ®Google Scholar
• Rankin BJ , SrivastavaED , RecordCO , PearsonJP , AllenA. Patients with ulcerative colitis have reduced mucin polymer content in the adherent colonic mucus gel. Biochem. Soc. Trans.23(1), 104S (1995).
   PubMed Web of Science ®Google Scholar
• Strugala V , DettmarPW , PearsonJP. Thickness and continuity of the adherent colonic mucus barrier in active and quiescent ulcerative colitis and Crohn's disease. Int. J. Clin. Pract.62(5), 762–769 (2008).
   PubMed Web of Science ®Google Scholar
• Larsson JMH , KarlssonH , CrespoJGet al. Altered O-glycosylation profile of MUC2 mucin occurs in active ulcerative colitis and is associated with increased inflammation. Inflamm. Bowel Dis.17(11), 2299–2307 (2011).
   PubMed Web of Science ®Google Scholar
• Mankertz J , SchulzkeJ-D. Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications. Curr. Opin. Gastroenterol.23(4), 379–383 (2007).
   PubMed Web of Science ®Google Scholar
• Bruewer M , SamarinS , NusratA. Inflammatory bowel disease and the apical junctional complex. Ann. N. Y. Acad. Sci.1072(1), 242–252 (2006).
   PubMedGoogle Scholar
• Tirosh B , KhatibN , BarenholzY , NissanA , RubinsteinA. Transferrin as a luminal target for negatively charged liposomes in the inflamed colonic mucosa. Mol. Pharm.6(4), 1083–1091 (2009).
   PubMed Web of Science ®Google Scholar
• Frank DN , StAmand AL , FeldmanRA , BoedekerEC , HarpazN , PaceNR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl Acad. Sci. USA104(34), 13780–13785 (2007).
   PubMed Web of Science ®Google Scholar
• Manichanh C , Rigottier-GoisL , BonnaudEet al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut55(2), 205–211 (2006).
   PubMed Web of Science ®Google Scholar
• Mcconnell EL , FaddaHM , BasitAW. Gut instincts: explorations in intestinal physiology and drug delivery. Int. J. Pharm.364(2), 213–226 (2008).
   PubMed Web of Science ®Google Scholar
• Fallingborg J , ChristensenLA , JacobsenBA , RasmussenSN. Very low intraluminal colonic pH in patients with active ulcerative colitis. Dig. Dis. Sci.38(11), 1989–1993 (1993).
   PubMed Web of Science ®Google Scholar
• Nugent SG , KumarD , RamptonDS , EvansDF. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut48(4), 571 (2001).
   PubMed Web of Science ®Google Scholar
• Sasaki Y , HadaR , NakajimaH , FukudaS , MunakataA. Improved localizing method of radiopill in measurement of entire gastrointestinal pH profiles: colonic luminal pH in normal subjects and patients with Crohn's disease. Am. J. Gastroenterol.92(1), 114–118 (1997).
   PubMed Web of Science ®Google Scholar
• Siccardi D , TurnerJR , MrsnyRJ. Regulation of intestinal epithelial function: a link between opportunities for macromolecular drug delivery and inflammatory bowel disease. Adv. Drug Deliv. Rev.57(2), 219–235 (2005).
   PubMed Web of Science ®Google Scholar
• Date AA , HanesJ , EnsignLM. Nanoparticles for oral delivery: design, evaluation and state-of-the-art. J. Control. Rel.240, 504–526 (2016).
   PubMed Web of Science ®Google Scholar
• Lamprecht A , YamamotoH , TakeuchiH , KawashimaY. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J. Pharmacol. Exp. Ther.315(1), 196–202 (2005).
   PubMed Web of Science ®Google Scholar
• Xiao B , LarouiH , AyyaduraiSet al. Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-α RNA interference for IBD therapy. Biomaterials34(30), 7471–7482 (2013).
   PubMed Web of Science ®Google Scholar
• Huang Y , GuoJ , GuiS. Orally targeted galactosylated chitosan poly(lactic-co-glycolic acid) nanoparticles loaded with TNF-α siRNA provide a novel strategy for the experimental treatment of ulcerative colitis. Eur. J. Pharm. Sci.125, 232–243 (2018).
   PubMed Web of Science ®Google Scholar
• Laroui H , ViennoisE , XiaoBet al. Fab'-bearing siRNA TNFα-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis. J. Control. Rel.186, 41–53 (2014).
   PubMed Web of Science ®Google Scholar
• Xiao B , XuZ , ViennoisEet al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol. Ther.25(7), 1628–1640 (2017).
   PubMed Web of Science ®Google Scholar
• Moulari B , BéduneauA , PellequerY , LamprechtA. Lectin-decorated nanoparticles enhance binding to the inflamed tissue in experimental colitis. J. Control. Release188, 9–17 (2014).
   PubMed Web of Science ®Google Scholar
• Das Neves J , BahiaMF , AmijiMM , SarmentoB. Mucoadhesive nanomedicines: characterization and modulation of mucoadhesion at the nanoscale. Expert Opin. Drug Deliv.8(8), 1085–1104 (2011).
   PubMed Web of Science ®Google Scholar
• Sosnik A , DasNeves J , SarmentoB. Mucoadhesive polymers in the design of nano-drug delivery systems for administration by non-parenteral routes: a review. Prog. Polym. Sci.39(12), 2030–2075 (2014).
   Web of Science ®Google Scholar
• Niebel W , WalkenbachK , BéduneauA , PellequerY , LamprechtA. Nanoparticle-based clodronate delivery mitigates murine experimental colitis. J. Control. Rel.160(3), 659–665 (2012).
   PubMed Web of Science ®Google Scholar
• Lautenschlager C , SchmidtC , LehrCM , FischerD , StallmachA. PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease. Eur J. Pharm. Biopharm.85(3 Pt A), 578–586 (2013).
   PubMed Web of Science ®Google Scholar
• Coco R , PlapiedL , PourcelleVet al. Drug delivery to inflamed colon by nanoparticles: comparison of different strategies. Int. J. Pharm.440(1), 3–12 (2013).
   PubMed Web of Science ®Google Scholar
• Lai SK , O’HanlonDE , HarroldSet al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl Acad. Sci. USA104(5), 1482–1487 (2007).
   PubMed Web of Science ®Google Scholar
• Cu Y , SaltzmanWM. Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus. Mol. Pharm.6(1), 173–181 (2009).
   PubMed Web of Science ®Google Scholar
• Maisel K , EnsignL , ReddyM , ConeR , HanesJ. Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse. J. Control. Rel.197, 48–57 (2015).
   PubMed Web of Science ®Google Scholar
• Nunes R , AraujoF , TavaresJ , SarmentoB , DasNeves J. Surface modification with polyethylene glycol enhances colorectal distribution and retention of nanoparticles. Eur J. Pharm. Biopharm.130, 200–206 (2018).
   PubMed Web of Science ®Google Scholar
• Sadio A , AmaralAL , NunesRet al. A mouse intra-intestinal infusion model and its application to the study of nanoparticle distribution. Front. Physiol.7, 579 (2016).
   PubMed Web of Science ®Google Scholar
• Kotla NG , RanaS , SivaramanGet al. Bioresponsive drug delivery systems in intestinal inflammation: State-of-the-art and future perspectives. Adv. Drug Deliv. Rev. doi:10.1016/j.addr.2018.06.021 (2018) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Zeeshan M , AliH , KhanS , KhanSA , WeigmannB. Advances in orally-delivered pH-sensitive nanocarrier systems; an optimistic approach for the treatment of inflammatory bowel disease. Int. J. Pharm.558, 201–214 (2019).
   PubMed Web of Science ®Google Scholar
• Beloqui A , CocoR , MemvangaPB , UcakarB , DesRieux A , PreatV. pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease. Int. J. Pharm.473(1–2), 203–212 (2014).
   PubMed Web of Science ®Google Scholar
• Makhlof A , TozukaY , TakeuchiH. pH-Sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model. Eur J. Pharm. Biopharm.72(1), 1–8 (2009).
   PubMed Web of Science ®Google Scholar
• Lih-Brody L , PowellSR , CollierKPet al. Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig. Dis. Sci.41(10), 2078–2086 (1996).
   PubMed Web of Science ®Google Scholar
• Sedghi S , FieldsJZ , KlamutMet al. Increased production of luminol enhanced chemiluminescence by the inflamed colonic mucosa in patients with ulcerative colitis. Gut34(9), 1191–1197 (1993).
   PubMed Web of Science ®Google Scholar
• Bertoni S , LiuZ , CorreiaAet al. pH and reactive oxygen species-sequential responsive nano-in-micro composite for targeted therapy of inflammatory bowel disease. Adv. Funct. Mater.28(50), 1806175 (2018).
   Web of Science ®Google Scholar
• Wang Y , ParkerCE , BhanjiT , FeaganBG , MacDonaldJK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev.4, Cd000543 (2016).
   Google Scholar
• Ford AC , KhanKJ , AchkarJ-P , MoayyediP. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis. Am. J. Gastroenterol.107(2), 167–176 (2012).
   PubMed Web of Science ®Google Scholar
• Ordás I , EckmannL , TalaminiM , BaumgartDC , SandbornWJ. Ulcerative colitis. Lancet380(9853), 1606–1619 (2012).
   PubMed Web of Science ®Google Scholar
• Lamprecht A . Multiparticulate systems in the treatment of inflammatory bowel disease. Curr. Drug Targets Inflamm. Allergy2(2), 137–144 (2003).
   PubMedGoogle Scholar
• Pertuit D , MoulariB , BetzTet al. 5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. J. Control. Release123(3), 211–218 (2007).
   PubMed Web of Science ®Google Scholar
• Iwao Y , TomiguchiI , DomuraAet al. Inflamed site-specific drug delivery system based on the interaction of human serum albumin nanoparticles with myeloperoxidase in a murine model of experimental colitis. Eur J. Pharm. Biopharm.125, 141–147 (2018).
   PubMed Web of Science ®Google Scholar
• Moulari B , PertuitD , PellequerY , LamprechtA. The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis. Biomaterials29(34), 4554–4560 (2008).
   PubMed Web of Science ®Google Scholar
• Tang H , XiangD , WangF , MaoJ , TanX , WangY. 5-ASA-loaded SiO2 nanoparticles-a novel drug delivery system targeting therapy on ulcerative colitis in mice. Mol. Med. Rep.15(3), 1117–1122 (2017).
   PubMed Web of Science ®Google Scholar
• Winterbourn CC , KettleAJ. Biomarkers of myeloperoxidase-derived hypochlorous acid. Free Radic. Biol. Med.29(5), 403–409 (2000).
   PubMed Web of Science ®Google Scholar
• Alagozlu H , GorgulA , BilgihanA , TuncerC , UnalS. Increased plasma levels of advanced oxidation protein products (AOPP) as a marker for oxidative stress in patients with active ulcerative colitis. Clin. Res. Hepatol. Gastroenterol.37(1), 80–85 (2013).
   PubMed Web of Science ®Google Scholar
• Chopra A , PardiDS , LoftusEVJret al. Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice. Inflamm. Bowel Dis.12(1), 29–32 (2006).
   PubMed Web of Science ®Google Scholar
• Fedorak RN , BistritzL. Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv. Drug Deliv. Rev.57(2), 303–316 (2005).
   PubMed Web of Science ®Google Scholar
• Sun Q , LuanL , ArifMet al. Redox-sensitive nanoparticles based on 4-aminothiophenol-carboxymethyl inulin conjugate for budesonide delivery in inflammatory bowel diseases. Carbohydr. Polym.189, 352–359 (2018).
   PubMed Web of Science ®Google Scholar
• Naeem M , ChoiM , CaoJet al. Colon-targeted delivery of budesonide using dual pH- and time-dependent polymeric nanoparticles for colitis therapy. Drug Des. Devel. Ther.9, 3789–3799 (2015).
   PubMed Web of Science ®Google Scholar
• Naeem M , KimW , CaoJ , JungY , YooJW. Enzyme/pH dual sensitive polymeric nanoparticles for targeted drug delivery to the inflamed colon. Colloids Surf. B Biointerfaces123, 271–278 (2014).
   PubMed Web of Science ®Google Scholar
• Li W , LiY , LiuZet al. Hierarchical structured and programmed vehicles deliver drugs locally to inflamed sites of intestine. Biomaterials185, 322–332 (2018).
   PubMed Web of Science ®Google Scholar
• Date AA , HalpertG , BabuTet al. Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease. Biomaterials185, 97–105 (2018).
   PubMed Web of Science ®Google Scholar
• Nguyen CTH , WebbRI , LambertLKet al. Bifunctional succinylated ϵ-polylysine-coated mesoporous silica nanoparticles for pH-responsive and intracellular drug delivery targeting the colon. ACS Appl. Mater. Interfaces9(11), 9470–9483 (2017).
   PubMed Web of Science ®Google Scholar
• Higa LH , JerezHE , DeFarias MA , PortugalRV , RomeroEL , MorillaMJ. Ultra-small solid archaeolipid nanoparticles for active targeting to macrophages of the inflamed mucosa. Nanomedicine12(10), 1165–1175 (2017).
   PubMed Web of Science ®Google Scholar
• Wang X , YanJ-J , WangLet al. Rational design of polyphenol-poloxamer nanovesicles for targeting inflammatory bowel disease therapy. Chem. Mater.30(12), 4073–4080 (2018).
   Web of Science ®Google Scholar
• Isaacs KL , LewisJD , SandbornWJ , SandsBE , TarganSR. State of the art: IBD therapy and clinical trials in IBD. Inflamm. Bowel Dis.11(Suppl. 1), S3–S12 (2005).
   PubMedGoogle Scholar
• Courthion H , MugnierT , RousseauxC , MöllerM , GurnyR , GabrielD. Self-assembling polymeric nanocarriers to target inflammatory lesions in ulcerative colitis. J. Control. Rel.275, 32–39 (2018).
   PubMed Web of Science ®Google Scholar
• Guada M , SebastianV , IrustaS , FeijooE , Dios-VieitezMdel C , Blanco-PrietoMJ. Lipid nanoparticles for cyclosporine A administration: development, characterization, and in vitro evaluation of their immunosuppression activity. Int. J. Nanomed.10, 6541–6553 (2015).
   PubMed Web of Science ®Google Scholar
• Guada M , BeloquiA , AlhouayekMet al. Cyclosporine A-loaded lipid nanoparticles in inflammatory bowel disease. Int. J. Pharm.503(1–2), 196–198 (2016).
   PubMedGoogle Scholar
• Melero A , DraheimC , HansenSet al. Targeted delivery of cyclosporine A by polymeric nanocarriers improves the therapy of inflammatory bowel disease in a relevant mouse model. Eur J. Pharm. Biopharm.119, 361–371 (2017).
   PubMed Web of Science ®Google Scholar
• Naeem M , BaeJ , OshiMAet al. Colon-targeted delivery of cyclosporine A using dual-functional Eudragit((R)) FS30D/PLGA nanoparticles ameliorates murine experimental colitis. Int. J. Nanomed.13, 1225–1240 (2018).
   PubMed Web of Science ®Google Scholar
• Bak A , AshfordM , BraydenDJ. Local delivery of macromolecules to treat diseases associated with the colon. Adv. Drug Deliv. Rev.136–137, 2–27 (2018).
   PubMed Web of Science ®Google Scholar
• Frede A , NeuhausB , KlopfleischRet al. Colonic gene silencing using siRNA-loaded calcium phosphate/PLGA nanoparticles ameliorates intestinal inflammation in vivo. J. Control. Rel.222, 86–96 (2016).
   PubMed Web of Science ®Google Scholar
• Laroui H , GeemD , XiaoBet al. Targeting intestinal inflammation with CD98 siRNA/PEI-loaded nanoparticles. Mol. Ther.22(1), 69–80 (2014).
   PubMed Web of Science ®Google Scholar
• Sitaraman SV , TheissAL , MerlinDet al. Nanoparticle-based therapeutic delivery of prohibitin to the colonic epithelial cells ameliorates acute murine colitis. Inflamm. Bowel Dis.17(5), 1163–1176 (2010).
   PubMed Web of Science ®Google Scholar
• Zuo L , HuangZ , DongLet al. Targeting delivery of anti-TNFas oligonucleotide into activated colonic macrophages protects against experimental colitis. Gut59(4), 470–479 (2010).
   PubMed Web of Science ®Google Scholar
• Cheng W , TangC , YinC. Effects of particle size and binding affinity for small interfering RNA on the cellular processing, intestinal permeation and anti-inflammatory efficacy of polymeric nanoparticles. J. Gene Med.17(10–12), 244–256 (2015).
   PubMed Web of Science ®Google Scholar
• Laroui H , DalmassoG , NguyenHT , YanY , SitaramanSV , MerlinD. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology138(3), 843–853, (2010).
   PubMed Web of Science ®Google Scholar
• Kriegel C , AttarwalaH , AmijiM. Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tract. Adv. Drug Deliv. Rev.65(6), 891–901 (2013).
   PubMed Web of Science ®Google Scholar
• Kriegel C , AmijiM. Oral TNF-alpha gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. J. Control. Rel.150(1), 77–86 (2011).
   PubMed Web of Science ®Google Scholar
• Kriegel C , AmijiMM. Dual TNF-α/Cyclin D1 gene silencing with an oral polymeric microparticle system as a novel strategy for the treatment of inflammatory bowel disease. Clin. Transl. Gastroenterol.2(3), e2 (2011).
   PubMedGoogle Scholar
• Bhavsar MD , AmijiMM. Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther.15(17), 1200–1209 (2008).
   PubMed Web of Science ®Google Scholar
• Bhavsar MD , AmijiMM. Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS). J. Control. Rel.119(3), 339–348 (2007).
   PubMed Web of Science ®Google Scholar
• Bhavsar MD , AmijiMM. Development of novel biodegradable polymeric nanoparticles-in-microsphere formulation for local plasmid DNA delivery in the gastrointestinal tract. AAPS PharmSciTech9(1), 288–294 (2008).
   PubMed Web of Science ®Google Scholar
• Tian Y , XuJ , LiYet al. MicroRNA-31 reduces inflammatory signaling and promotes regeneration in colon epithelium, and delivery of mimics in microspheres reduces colitis in mice. Gastroenterology156(8) 2281– 2296 (2019).
   PubMed Web of Science ®Google Scholar
• Schmidt C , LautenschlaegerC , CollnotEMet al. Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: a first in vivo study in human patients. J. Control. Rel.165(2), 139–145 (2013).
   PubMed Web of Science ®Google Scholar
• Melo M , NunesR , SarmentoB , DasNeves J. Rectal administration of nanosystems: from drug delivery to diagnostics. Mater. Today Chem.10, 128–141 (2018).
   Web of Science ®Google Scholar
• Tinkle S , McNeilSE , MühlebachSet al. Nanomedicines: addressing the scientific and regulatory gap. Ann. N. Y. Acad. Sci.1313(1), 35–56 (2014).
   PubMed Web of Science ®Google Scholar
• Hua S , DeMatos MBC , MetselaarJM , StormG. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization. Front. Pharmacol.9, 790–790 (2018).
   PubMed Web of Science ®Google Scholar
• Yang C , YuD-G , PanDet al. Electrospun pH-sensitive core–shell polymer nanocomposites fabricated using a tri-axial process. Acta Biomater.35, 77–86 (2016).
   PubMed Web of Science ®Google Scholar
• Duan B , LiM , SunY , ZouS , XuX. Orally delivered antisense oligodeoxyribonucleotides of TNF-α via polysaccharide-based nanocomposites targeting intestinal inflammation. Adv. Healthc. Mater.8(5), 1801389 (2019).
   Web of Science ®Google Scholar
• Elinav E , PeerD. Harnessing nanomedicine for mucosal theranostics -- a silver bullet at last?ACS Nano7(4), 2883–2890 (2013).
   PubMed Web of Science ®Google Scholar
• Jin M , YuD-G , WangX , GeraldesCFGC , WilliamsGR , BlighSWA. Electrospun contrast-agent-loaded fibers for colon-targeted MRI. Adv. Healthc. Mater.5(8), 977–985 (2016).
   PubMed Web of Science ®Google Scholar
• Jin M , YuD-G , GeraldesCFGC , WilliamsGR , BlighSWA. Theranostic fibers for simultaneous imaging and drug delivery. Mol. Pharm.13(7), 2457–2465 (2016).
   PubMedGoogle Scholar